🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Mario Sznol

Yale Cancer Center

ORCID: 0000-0003-4137-9662

Also affiliated with Yale University

MedicineBiochemistry, Genetics and Molecular BiologyImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

2in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 9 papers. Top paper: “First-in-human phase Ib trial of M9241 (NHS-IL12) plus avelumab in patients with advanced solid tumors, including dose expansion in patients with advanced urothelial carcinoma”.

First-in-human phase Ib trial of M9241 (NHS-IL12) plus avelumab in patients with advanced solid tumors, including dose expansion in patients with advanced urothelial carcinoma

Journal for ImmunoTherapy of Cancer(2023)10.1136/jitc-2022-005813
N/A
0.810DataRank · unranked
25 citations

Jean‐Laurent Deville, Mario Sznol, Alain Ravaud, Marco Maruzzo, Russell K. Pachynski +14 more

A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non–Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-0903
N/A
0.694DataRank · unranked
101 citations

Dijana Djureinovic, Shlomit Jessel, Irina Krykbaeva, Lin Zhang, Lucia Jilaveanu +17 more

Subsets of IFN Signaling Predict Response to Immune Checkpoint Blockade in Patients with Melanoma

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-0215
N/A
0.360DataRank · unranked
10 citations

Daniel Y. Lee, Min Ding, Sandra Martínez-Morilla, Thazin Nwe Aung, Feriel Ouerghi +8 more

Integrative molecular and clinical profiling of acral melanoma identifies LZTR1 as a key tumor promoter and therapeutic target

bioRxiv (Cold Spring Harbor Laboratory)(2021)10.1101/2021.04.20.440286
N/A
0.165DataRank · unranked
2 citations

Xiang Chen, Chaya Levovitz, James Knight, Antonella Bacchiocchi, Juan Su +20 more

Integrative molecular and clinical profiling of acral melanoma links focal amplification of 22q11.21 to metastasis

Nature Communications(2022)10.1038/s41467-022-28566-4
N/A
0DataRank · unranked
66 citations

Kahn Rhrissorrakrai, Chaya Levovitz, Xiang Chen, James Knight, Antonella Bacchiocchi +19 more

Subsets of interferon signaling and response to immune checkpoint blockade.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.9522
N/A
0DataRank · unranked
0 citations

Brooke Horowitch, Min Ding, Sandra Martínez-Morilla, Thazin Nwe Aung, Feriel Ouerghi +8 more

LZTR1 is a melanoma oncogene that promotes invasion and suppresses apoptosis

Oncogene(2025)10.1038/s41388-025-03538-2
N/A
0DataRank · unranked
2 citations

Michael Mak, Zerin Mahzabin Khan, Xiangyu Gong, Mario Sznol, Zhenkun Na +9 more

Distinct immunologic changes in vivo following combination versus individual PD-1 or CTLA-4 checkpoint blockade in human cancer

Journal for ImmunoTherapy of Cancer(2014)10.1186/2051-1426-2-s3-o7
N/A
0DataRank · unranked
0 citations

Rakesh Verma, Mario Sznol, Chandra Sekhar Boddupalli, Scott Gettinger, Harriet Kluger +3 more

Integrative Molecular and Clinical Profiling of Acral Melanoma Identifies LZTR1 as a Key Tumor Promoter and Therapeutic Target

Research Square(2021)10.21203/rs.3.rs-110475/v1
N/A
0DataRank · unranked
1 citations

Aaron M. Newman, Farshad Farshidfar, Cong Peng, Chaya Levovitz, James Knight +20 more